⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23771904 | 0.82 | — | — | |
| SCHEMBL5959941 | 0.79 | TRPA1 (0.39) | — | |
| SCHEMBL16287910 | 0.74 | — | — | |
| SCHEMBL16288397 | 0.74 | — | — | |
| SCHEMBL1015589 | 0.73 | — | — | |
| SCHEMBL16288911 | 0.71 | — | — | |
| SCHEMBL12396800 | 0.70 | GPR84 (0.31) | — | |
| SCHEMBL16287956 | 0.70 | — | — | |
| SCHEMBL12361597 | 0.70 | — | — | |
| SCHEMBL16287255 | 0.69 | RAB9A (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796696-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9591935-B2 | Therapeutic substituted cyclopentanes | ALLERGEN, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-20170057941-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. | 2017-03-02 | — | — | US | disclosed |
| US-9365485-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20150274658-A1 | THERAPEUTIC LACTAMS | ALLERGAN, INC. (US) | 2015-10-01 | — | — | US | disclosed |
| US-20140323510-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2014-10-30 | — | — | US | disclosed |
| US-8722726-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-20130231322-A1 | THERAPEUTIC SUBSTITUTED BETA-LACTAMS | ALLERGAN, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-8440819-B2 | Therapeutic substituted beta-lactams | ALLERGAN, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-8003680-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20110062165-A1 | BALANCED INDIVIDUAL DINING PLATE | ALLERGAN INC | 2011-03-17 | — | — | US | disclosed |
| US-20100048669-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-7659295-B2 | 5-(3-(3-(4-(1-hydroxyhexyl)phenyl)-4-oxo-thiazolidin-2-yl)propyl)thiophene-2-carboxylic acid; prostaglandin agonist; ocular hypotensive agents; post-surgical and post-laser trabeculectomy ocular hypertensive episodes, glaucoma, and as presurgical adjuncts | ALLERGAN, INC. (US) | 2010-02-09 | — | — | US | disclosed |
| US-7605178-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-20090215740-A1 | THERAPEUTIC SUBSTITUTED BETA-LACTAMS | ALLERGAN, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-7507833-B2 | Therapeutic N-aryl or N-heteroaryl pyrazolidine and pyrazolidinone derivatives | ALLERGAN, INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-20080119539-A1 | THERAPEUTIC AMIDES | ALLERGAN, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080119538-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080058387-A1 | 5-(3-(3-(4-(1-hydroxyhexyl)phenyl)-4-oxo-thiazolidin-2-yl)propyl)thiophene-2-carboxylic acid; prostaglandin agonist; ocular hypotensive agents; post-surgical and post-laser trabeculectomy ocular hypertensive episodes, glaucoma, and as presurgical adjuncts | ALLERGAN, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080045576-A1 | THERAPEUTIC N-ARYL OR N-HETEROARYL PYRAZOLIDINE AND PYRAZOLIDINONE DERIVATIVES | ALLERGAN, INC. | 2008-02-21 | — | — | US | disclosed |